Cited 38 times in
Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김중선 | - |
dc.contributor.author | 신동호 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김승환 | - |
dc.date.accessioned | 2014-12-18T08:21:36Z | - |
dc.date.available | 2014-12-18T08:21:36Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0002-9149 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/86160 | - |
dc.description.abstract | There have been no optical coherence tomographic (OCT) data directly comparing the pattern of strut coverage between the 2 second-generation drug-eluting stents in the early period. The aim of this prospective study was to evaluate early strut coverage using optical coherence tomography 3 months after Resolute zotarolimus-eluting stent (ZES-R) or everolimus-eluting stent (EES) implantation in de novo coronary artery lesions. A total of 40 patients who were suitable for the OCT procedure and consented to the study protocol were randomized 1:1 to receive either ZES-R or EES. Among these patients, 35 stented lesions (18 ZES-R, 17 EES) in 34 patients were evaluated by optical coherence tomography immediately and 3 months after stent implantation. Neointimal hyperplasia thickness, percentage of uncovered struts, and the proportion of malapposed struts were measured at 1-mm intervals. An uncovered strut was defined as having a neointimal hyperplasia thickness of 0 μm. At the 3-month OCT evaluation, mean neointimal hyperplasia thickness (ZES-R vs EES 74 ± 41 vs 75 ± 35 μm, p = 0.89) and mean percentage of uncovered struts (ZES-R vs EES 6.2 ± 6.9 vs 4.7 ± 5.1%, p = 0.62) were not significantly different between the groups. The percentage of malapposed struts was also similar between the groups (0.7 ± 2.2% for ZES-R and 0.7 ± 1.7% for EES, p = 0.64). Thrombi were documented in 3 stents (1 [5.6%] in a ZES-R vs 2 [11.8%] in EES, p = 0.60). In conclusion, early stent strut coverage on the basis of serial OCT evaluation was comparable between ZES-R and EES 3 months after stent implantation | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents | - |
dc.subject.MESH | Coronary Angiography | - |
dc.subject.MESH | Coronary Restenosis/diagnosis | - |
dc.subject.MESH | Coronary Restenosis/prevention & control | - |
dc.subject.MESH | Coronary Stenosis/diagnosis | - |
dc.subject.MESH | Coronary Stenosis/surgery* | - |
dc.subject.MESH | Coronary Vessels/pathology* | - |
dc.subject.MESH | Coronary Vessels/ultrastructure | - |
dc.subject.MESH | Drug-Eluting Stents | - |
dc.subject.MESH | Everolimus | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents/pharmacology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neointima/pathology* | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Sirolimus/analogs & derivatives* | - |
dc.subject.MESH | Sirolimus/pharmacology | - |
dc.subject.MESH | Tomography, Optical Coherence/methods* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Ultrasonography, Interventional | - |
dc.title | Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Seunghwan Kim | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Dong-Ho Shin | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Yun-Kyeong Cho | - |
dc.contributor.googleauthor | Chang-Wook Nam | - |
dc.contributor.googleauthor | Seung-Ho Hur | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.identifier.doi | 10.1016/j.amjcard.2012.08.037 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A02097 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00669 | - |
dc.relation.journalcode | J00071 | - |
dc.identifier.eissn | 1879-1913 | - |
dc.identifier.pmid | 23040589 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0002914912020541 | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Antineoplastic Agents | - |
dc.subject.keyword | Coronary Angiography | - |
dc.subject.keyword | Coronary Restenosis/diagnosis | - |
dc.subject.keyword | Coronary Restenosis/prevention & control | - |
dc.subject.keyword | Coronary Stenosis/diagnosis | - |
dc.subject.keyword | Coronary Stenosis/surgery* | - |
dc.subject.keyword | Coronary Vessels/pathology* | - |
dc.subject.keyword | Coronary Vessels/ultrastructure | - |
dc.subject.keyword | Drug-Eluting Stents | - |
dc.subject.keyword | Everolimus | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Follow-Up Studies | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Immunosuppressive Agents/pharmacology | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Neointima/pathology* | - |
dc.subject.keyword | Prospective Studies | - |
dc.subject.keyword | Sirolimus/analogs & derivatives* | - |
dc.subject.keyword | Sirolimus/pharmacology | - |
dc.subject.keyword | Tomography, Optical Coherence/methods* | - |
dc.subject.keyword | Treatment Outcome | - |
dc.subject.keyword | Ultrasonography, Interventional | - |
dc.contributor.alternativeName | Kim, Jung Sun | - |
dc.contributor.alternativeName | Shin, Dong Ho | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.alternativeName | Choi, Dong Hoon | - |
dc.contributor.alternativeName | Hong, Myeong Ki | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.alternativeName | Kim, Byeong Keuk | - |
dc.contributor.alternativeName | Kim, Seung Hwan | - |
dc.contributor.affiliatedAuthor | Kim, Jung Sun | - |
dc.contributor.affiliatedAuthor | Shin, Dong Ho | - |
dc.contributor.affiliatedAuthor | Jang, Yang Soo | - |
dc.contributor.affiliatedAuthor | Choi, Dong Hoon | - |
dc.contributor.affiliatedAuthor | Hong, Myeong Ki | - |
dc.contributor.affiliatedAuthor | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | Kim, Byeong Keuk | - |
dc.contributor.affiliatedAuthor | Kim, Seung Hwan | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 111 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 5 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CARDIOLOGY, Vol.111(1) : 1-5, 2013 | - |
dc.identifier.rimsid | 28821 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.